Do You Need to Assess Myocardial Ischemia in Type 2 Diabetes

Randomized Strategy Trial Comparing Detection of Silent Ischemia With no Detection of Silent Ischemia in Asymptomatic Patients With Type 2 Diabetes Mellitus. Effects on Cardiovascular Events.

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00627783

Acronym

DYNAMIT

Enrollment

642

Registered

2008-03-03

Start date

2000-12-31

Completion date

2005-07-31

Last updated

2008-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

DYNAMIT is a prospective, randomized, multicenter, open strategy trial run in 45 French hospitals. Diabetic patients with no evidence of coronary artery disease and at least 2 additional cardiovascular risk factors are randomized to screening for silent ischemia using a bicycle exercise test or Dipyridamole Single Photon Emission Computed Tomography (N=316), or follow-up without screening (N=315). All have access to cardiovascular prevention according current guidelines. The main end point is time to death from all causes, non-fatal myocardial infarction, non-fatal stroke, or heart failure requiring hospitalization or emergency service intervention.

Interventions

OTHERa bicycle exercise test

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

55 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients 55 to 75 years old had type-2 diabetes and at least two of the following cardiovascular risk factors: * urinary albumin excretion \> 30 mg/L or \> 30 mg/24 hours, * treated or untreated hypertension, * treated or untreated lipid abnormality, * peripheral arterial disease, * history of transient ischemic accident, * tobacco consumption * familial history of premature cardiovascular disease.

Exclusion criteria

* History of myocardial infarction, coronary artery disease, or stroke, * Previous positive stress test or myocardial perfusion imaging, * Negative stress test or myocardial perfusion imaging within the last three years

Design outcomes

Primary

Measure	Time frame
Death from all causes, non-fatal myocardial infarction, non-fatal stroke, or heart failure requiring hospitalization or emergency service intervention, measured after a minimum follow-up of 2 years	—

Secondary

Measure	Time frame
Unstable angina requiring hospitalization Coronary events Coronary revascularization	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026